BR112023005393A2 - Variantes de anticorpos caninos - Google Patents

Variantes de anticorpos caninos

Info

Publication number
BR112023005393A2
BR112023005393A2 BR112023005393A BR112023005393A BR112023005393A2 BR 112023005393 A2 BR112023005393 A2 BR 112023005393A2 BR 112023005393 A BR112023005393 A BR 112023005393A BR 112023005393 A BR112023005393 A BR 112023005393A BR 112023005393 A2 BR112023005393 A2 BR 112023005393A2
Authority
BR
Brazil
Prior art keywords
canine antibody
antibody variants
canine
present
relates
Prior art date
Application number
BR112023005393A
Other languages
English (en)
Inventor
Marie Bergeron Lisa
Luis CAMPOS Henry
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of BR112023005393A2 publication Critical patent/BR112023005393A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

VARIANTES DE ANTICORPOS CANINOS. A presente invenção refere-se geralmente a variantes de anticorpo canino e usos das mesmas. Especificamente, a presente invenção refere-se a mutações na região constante do anticorpo canino para melhorar sua meia-vida e outros aspectos.
BR112023005393A 2020-09-28 2021-09-28 Variantes de anticorpos caninos BR112023005393A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063084241P 2020-09-28 2020-09-28
PCT/US2021/052338 WO2022067233A2 (en) 2020-09-28 2021-09-28 Canine antibody variants

Publications (1)

Publication Number Publication Date
BR112023005393A2 true BR112023005393A2 (pt) 2023-04-25

Family

ID=78599123

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023005393A BR112023005393A2 (pt) 2020-09-28 2021-09-28 Variantes de anticorpos caninos

Country Status (17)

Country Link
US (1) US20240010716A1 (pt)
EP (1) EP4217384A2 (pt)
JP (1) JP2023543262A (pt)
KR (1) KR20230079148A (pt)
CN (1) CN116438196A (pt)
AR (1) AR123636A1 (pt)
AU (1) AU2021349301A1 (pt)
BR (1) BR112023005393A2 (pt)
CA (1) CA3194936A1 (pt)
CL (1) CL2023000878A1 (pt)
CO (1) CO2023004102A2 (pt)
EC (1) ECSP23030271A (pt)
IL (1) IL301413A (pt)
MX (1) MX2023003624A (pt)
PE (1) PE20231374A1 (pt)
TW (1) TW202229337A (pt)
WO (1) WO2022067233A2 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023250284A2 (en) * 2022-06-21 2023-12-28 Zoetis Services Llc Canine antibody mutants

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5698762A (en) 1994-12-09 1997-12-16 Dauerman; Leonard Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
KR20070057839A (ko) 2004-08-19 2007-06-07 제넨테크, 인크. 변경된 이펙터 기능을 갖는 폴리펩티드 변이체
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
KR101027427B1 (ko) 2004-11-12 2011-04-11 젠코어 인코포레이티드 ＦcRn에 대하여 증가된 결합력을 갖는 Ｆc 변이체
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
HUE058226T2 (hu) 2010-08-19 2022-07-28 Zoetis Belgium S A NGF elleni antitestek és alkalmazásuk
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
AU2013271564A1 (en) 2012-06-06 2014-12-04 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
JP2022513653A (ja) * 2018-11-28 2022-02-09 ブリストル－マイヤーズ スクイブ カンパニー 修飾された重鎖定常領域を含む抗体
CN113227134A (zh) * 2018-12-05 2021-08-06 株式会社梅花治疗 抗体的Fc区变体
AU2020205073A1 (en) * 2019-01-03 2021-08-19 Invetx Inc. Compositions for increasing half-life of a therapeutic agent in canines and methods of use
IL297287A (en) * 2020-04-17 2022-12-01 Zoetis Services Llc Antibody variants for dogs

Also Published As

Publication number Publication date
TW202229337A (zh) 2022-08-01
ECSP23030271A (es) 2023-07-31
CA3194936A1 (en) 2022-03-31
EP4217384A2 (en) 2023-08-02
KR20230079148A (ko) 2023-06-05
PE20231374A1 (es) 2023-09-07
WO2022067233A3 (en) 2022-05-27
AU2021349301A1 (en) 2023-08-24
JP2023543262A (ja) 2023-10-13
MX2023003624A (es) 2023-04-11
CL2023000878A1 (es) 2023-10-20
AR123636A1 (es) 2022-12-28
WO2022067233A2 (en) 2022-03-31
CO2023004102A2 (es) 2023-04-05
US20240010716A1 (en) 2024-01-11
IL301413A (en) 2023-05-01
CN116438196A (zh) 2023-07-14

Similar Documents

Publication Publication Date Title
BR112022020944A2 (pt) Variantes de anticorpos caninos
ECSP22080858A (es) Variantes de anticuerpos felinos
CY1121236T1 (el) Ανθρωπινα αντισωματα εναντι της pcsk9 για χρηση σε μεθοδους θεραπειας συγκεκριμενων ομαδων ατομων
CO2023007146A2 (es) Variantes de anticuerpos bovinos
MX2021000392A (es) Anticuerpos anti-mesotelina.
BR112022011032A2 (pt) Conjugado de anticorpo-fármaco anti-claudina e uso farmacêutico do mesmo
BR112023005393A2 (pt) Variantes de anticorpos caninos
EA202192606A1 (ru) Антитела к пироглутамат--амилоиду и их применение
BR112018008900A2 (pt) composições compreendendo anticorpos para il6r para o tratamento de uveíte e edema macular e métodos de uso das mesmas
EA202092085A1 (ru) ТЕРАПЕВТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ sPLA2-GIB И ИХ ПРИМЕНЕНИЕ
AR096890A1 (es) Conjugando fc de inmunoglobulina, que mantiene la afinidad de unión del fragmento fc de la inmunoglobulina a fcrn
CO2023009994A2 (es) Mutaciones en regiones constantes de anticuerpos caninos
CO2023007829A2 (es) Mutaciones en regiones constantes de anticuerpos felinos
EA201991736A1 (ru) Антитело против оболочечного herv-k и его применение
ECSP23030307A (es) Variantes de anticuerpos felinos
EA202192532A1 (ru) Мирикизумаб для применения в способе лечения болезни крона
BR112023001061A2 (pt) Anticorpos antiabeta
BR112022011122A2 (pt) Epítopos e anticorpos de trpv1
WO2020072279A3 (en) Deuterium depletion measurement
Nugroho ASSESSING SUSTAINABILITY OF LOW-COST HOUSING PROJECT THROUGH POST-OCCUPANCY EVALUATION IN SALATIGA CITY
EA201991614A1 (ru) СПЕЦИФИЧНЫЕ К ИЗОФОРМЕ, ПЕРМИССИВНЫЕ ПО ОТНОШЕНИЮ К КОНТЕКСТУ ИНГИБИТОРЫ TGFβ1 И ИХ ПРИМЕНЕНИЕ
BR112016001009A2 (pt) nova proteína de ornitina descarboxilase modificada e sua utilização